CHRONIC HEPATITIS C WITH MIXED CRYOGLOBULINEMIA: MODERN APPROACHES TO TREATMENT
DOI:
https://doi.org/10.11603/1681-2727.2016.2.6515Keywords:
chronic hepatitis C, mixed cryoglobulinemia, treatment.Abstract
Problematic issues of treatment of patients with chronic hepatitis C with mixed cryoglobulinemia are presented. It is shown that the eradication of virus hepatitis C is a main aim in treatment of patients with chronic hepatitis C with mixed cryoglobulinemia. At severe forms of the HCV-associated cryoglobulinema vasculitis it is expedient to consider possibilities of pathogenetic treatment.
References
Stefanova-Petrova D.V. Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia / D.V. Stefanova-Petrova // J. Gastroenterol. – 2007. – Vol. 13. – P. 6518-6528.
Sterling R.K. Extrahepatic manifestations of hepatitis C virus / R.K. Sterling, S. Bralow // Curr. Gastroenterol. Rep. – 2006. – Vol. 8. – P. 53-59.
Carles E.D. Hepatitis C virus-induced cryoglobulinemia / E.D. Carles, L.B. Dustin // Kidney International. – 2009. – Vol. 76. – P. 818-824.
The cryoglobulinaemias / [M. Ramos-Casals, J.H. Stone, M.C. Cid et al.] // Lancet. – 2012. – Vol. 379. – P. 348-360.
Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus related cryoglobulin vascular damage / [D. Sansonno, F.A. Tucci, B. Ghbrehiwet et al.] // J. Immunol. – 2009. – Vol. 183, N 9. – P. 6013-6020.
Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C / [P. Cacoub, T. Poynard, P. Ghillani et al.] // Arthritis Rheum. – 1999. – Vol. 42. – P. 2204-2212.
Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus associated symptomatic mixed cryoglobulinaemia / [J.L. Calleja, A. Albillos, R. Moreno-Otero et al.] // Aliment Pharmacol. Ther. – 1999. – Vol. 13. – P. 1179-1186.
Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus / [J.W. Levine, C. Gota, B.J. Fessler et al.] // J. Rheumatol. – 2005. – Vol. 32. – P. 1164-1167.
Craxi A. Hepatitis C virus (HCV) infection: a systemic disease / A. Craxi, G. Laffi, A.L. Zignego // Mol. Aspects Med. – 2008. – Vol. 29. – P. 85-95.
Kondratiuk L.O. Kriohlobulinemichnyi syndrom u khvorykh z khronichnym hepatytom S i mozhlyvosti yoho korektsii: Avtoref. dys. … k. med. n. / L.O. Kondratiuk. – Kyiv, 2015. – 22 s.
Riabokon Yu.Iu. Khronichnyi hepatyt S z pozapechinkovymy proiavamy: kliniko-patohenetychna rol neirohumoralnoi ta endotelialnoi dysfunktsii, optymizatsiia diahnostyky ta likuvannia: Avtoref. dys. … d. med. n. / Yu.Iu. Riabokon. – Ternopil, 2015. – 40 s.
Cacoub P. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis / P. Cacoub, O. Lidove, T. Maisonobe // Arthritis Rheum. – 2002. – Vol. 46. – P. 3317-3326.
Della Rossa A. Treatment of chronic hepatitis C infection with cryoglobulinemia / A. Della Rossa, A. Tavoni, C. Baldini // Curr. Opin. Rheumatol. – 2002. – Vol. 13. – P. 231-237.
Peg-IFN-alpha/Ribavirin/Protease inhibitor combination is highly effective in HCV-mixed cryoglobulinemia vasculitis / [D. Saadoun, S. Pol, P. Lebray et al.] // Hepatology. – 2012. – Vol. 56. – Abstract A790.
Batisse D. Sustained exacerbation of cryoglobulinemia-related vasculitis following treatment of hepatitis C with peginterferon-alfa / D. Batisse, M. Karmochkine // Eur. J. Gastroenterol. Hepatol. – 2004. – Vol. 16. – P. 701-703.
Beuthien W. Vasculitis complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature / W. Beuthien, H.U. Mellinghoff // Clin. Rheumatol. – 2005. – Vol. 30. – P. 369-371.
Kimyai-Asadi A. Mixed cryoglobulinemia secondary to interferon therapy for hepatitis C: case report and review of the literature / A. Kimyai-Asadi, K. Gohar, P. Kang // J. Drugs Dermatol. – 2002. – Vol. 1. – P. 72-75.
Cacoub P. PEGylated interferon alfa 2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis / P. Cacoub, D. Saadoun, N. Limal // Arthritis Rheum. – 2005. – Vol. 52. – P. 911-915.
Roccatello D. Long-term effects of anti-CD monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis / D. Roccatello, S. Baldovino, D. Rossi // Nephrol. Dial. Transplant. – 2004. – Vol. 19. – P. 3054-3061.
Ramos-Casals M. Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection / M. Ramos-Casals, O. Trejo, M. Garcia-Carrasco // Reumatology. – 2003. – Vol. 42. – P. 818-828.
Saadoun D. Therapeutic strategies in patients with HCV associated MC vasculitis / D. Saadoun // Reumatology. – 2007. – Vol. 46. – P. 1234-1242.
Ferri C. Mixed cryoglobulinemia / C. Ferri // Orph. J. Rare Dis. – 2008. – Vol. 3, N 25. – P. 2365-2370.
Cacoub P. Treatment of hepatitis C virus-related systemic vasculitis / P. Cacoub, D. Saadoun, D. Sene // J. Rheumatol. – 2005. – Vol. 32. – P. 2078-2082.
Schamberg N.J. Hepatitis C virus-related mixed cryoglobulinemia: pathogenesis, clinical manifestations, and new therapies / N.J. Schamberg, G.V. Lake-Bakaar // Gastroenterol. Hepatol. – 2007. – Vol. 3, N 9. – P. 695-703.
Saadoun D. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis / D. Saadoun, M. Rosenzwajg, F. Joly // N. Engl. J. Med. – 2011. – Vol. 365. – P. 2067-2076.
Deklaratsiinyi patent na vynakhid № 13766. Ukraina. Sposib terapii khvorykh na khronichni virusni hepatyty V i S z proiavamy systemnykh vaskulitiv / B.A. Herasun, V.V. Chopiak, O.B. Vorozhbyt. – Opubl. 17.04.06, Biul. № 4.
Weng W-K. Hepatitis C virus (HCV) and lymphomagenesis / W-K. Weng, S. Levy // Leukemia Lymphoma. – 2003. – Vol. 44. – P. 1112-1113.
Andreichyn M.A. Rol endotelialnoi dysfunktsii v perebihu khronichnoi HCV-infektsii ta yii korektsiia preparatom L-arhininu / M.A. Andreichyn, Yu.Iu. Riabokon // Infektsiini khvoroby. – 2012. – № 1 (67). – S. 31-39.
Deklaratsiinyi patent na korysnu model 71715. Ukraina, MPK (2012.01). Sposib vyboru taktyky patohenetychnoho likuvannia khronichnoho hepatytu S / Riabokon Yu.Iu. – № u 2012 00010; Zaiavl. 03.01.2012; Opubl. 25.07.2012. – Biul. № 14.
Forton D.M. Hepatitis C and cognitive impairment in a cohort of patient with mild liver disease / D.M. Forton, H.C. Thomas, C.A. Murphy // Hepatology. – 2002. – Vol. 35. – P. 433-439.
Andreichyn M.A. Ursodezoksykholeva kyslota u patohenetychnii terapii khronichnykh zakhvoriuvan pechinky / M.A. Andreichyn, O.V. Riabokon // Suchasni infektsii. – 2007. – № 1. – S. 30-35.
Vallisa D. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkins lymphoma: a multicenter Italian experience / D. Vallisa, P. Bernuzzi, L. Arcaini // J. Clin. Oncol. – 2005. – Vol. 23. – P. 468-473.
Benci A. Thrombocytopenia in patients with HCV-positive chronic hepatitis: efficacy of leukocyte interferon-alpha treatment / A. Benci, M. Caramani, D. Tacconi // Int. J. Clin. Pract. – 2003. – Vol. 57. – P. 17-19.
Doffoel-Hantz V. Evolution of Sjogren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin / V. Doffoel-Hantz, V. Loustand-Ratti, M. Ramos-Casala // Rev. Med. Intern. – 2005. – Vol. 26. – P. 88-94.
Downloads
Published
How to Cite
Issue
Section
License
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0